SuppFig1 - Type1 Receptor tissue expression
Tissue specific protein expression of BMPR1A and BMPR1B based on IHC. Data from the Protein Atlas (Uhlen et al., 2010).
SuppFig2 - Subcellular localisation of BMP receptors
Immunostaining of BMP receptors in three cancer cell lines showing intracellular localisation. U-2 OS is an osteosarcoma, A-431 is an epidermoid carcinoma and U-251/MG is a glioblastoma astrocytoma line. Green is receptor (Antibody CAB019398 for BMPR1A, HPA046821 for BMPR1B and HPA049014 for BMPR2) red is microtubules. Scale bar is 100 μm.
SuppFig3 - Prognostic affects of BMP pathway
Kaplan-Myer disease free survival curves in the TCGA sarcoma dataset (n=263) based on mRNA expression (top 10% and bottom 10% expressors). From top left; BMP2, BMP7, BMPR1A, BMPR1B and BMPR2.
SuppFig4 - Receptor expression by sarcoma subset
Median (± interquartile range) expression of BMPR1A, BMPR1B, BMPR2 and BMP2 in different sarcoma subsets. UPS is Undifferentiated Pleomorphic Sarcoma and LMS is Leiomyosarcoma.
SuppFig5 - BMP2 pan cancer
A: Pan-cancer analysis of BMP2 in several large scale genomics projects. Data from cBioPortal (cbioportal.org) (Cerami et al., 2012; Gao et al., 2013) . B: BMP2 interacting partners, defined in Cytoscape 3.2.1 (cytoscape.org) (Lopes et al., 2010) .
SuppFig6 - BMP2 pathway expression in several tumour types
Detailed waterfall plots for BMP pathway members deregulated (mutation, copy-number, up/down-regulation) in various cancer types. Vertical bars represent individual patients from the following cancer types: Sarcoma (provisional), Prostate (provisional), Breast (T. C. G. A. R. Network, 2012), Ovarian (T. C. G. A. R. Network, 2011), Lung (T. C. G. A. R. Network, 2014) and Head and Neck (T. C. G. A. Network, 2015). Visualisation was cBioPortal (cbioportal.org) (Cerami et al., 2012; Gao et al., 2013).
SuppFig7 - Prognostic ability of BMPR1A signature in other solid tumours
Kaplan-Myer disease free survival curves for BMPR1A-biased, BMPR1B-biased and BMPR2 signalling by high levels of endogenous BMP2. From top left, Prostate (provisional), Pancreatic (provisional), Lung (T. C. G. A. R. Network, 2014) and Ovarian (T. C. G. A. R. Network, 2011) cancers.
SuppTable1 - rhBMP2 new cancer events
Incidence of new cancers from a pivotal, multicentre, randomised controlled trial of patients with degenerative lumbar spine conditions who underwent a single-level instrumented posterolateral arthrodesis with either high-dose rhBMP-2 in a compression-resistant matrix (CRM) (rhBMP-2/CRM; n = 239) or autogenous bone graft (control group; n = 224).
Differential expression analysis from BMPR1A-biased and BMPR1B-biased BMP2 signalling in the TCGA sarcoma dataset
Differential expression analysis from BMPR1A-biased and BMPR1B-biased BMP2 signalling in the TCGA sarcoma dataset.